Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753282 | 0.79 | RAB9A (0.49) | GRM5PIK3C3MEN1KMT2A | |
| SCHEMBL16242119 | 0.74 | NPC1 (0.41) | HRH3 | |
| SCHEMBL3468289 | 0.72 | NPC1 (0.53) | HRH3 | |
| SCHEMBL19615775 | 0.70 | KDM4E (0.51) | PIK3C3HRH3 | |
| SCHEMBL22425338 | 0.69 | GRM5 (0.41) | GRM5PIK3C3MEN1KMT2A | |
| SCHEMBL18031408 | 0.69 | MELK (0.36) | PIK3C3 | |
| SCHEMBL30753293 | 0.68 | OPRM1 (0.42) | OPRM1GRM5MEN1KMT2AHRH3 | |
| SCHEMBL8953753 | 0.68 | L3MBTL1 (0.44) | MEN1KMT2A | |
| SCHEMBL5042317 | 0.67 | CYP3A4 (0.58) | GRM5KMT2A | |
| SCHEMBL8265695 | 0.66 | ALDH1A1 (0.49) | GRM5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565587-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B Technologies (Beijing) Co., Limited (CN) | 2025-06-11 | — | — | EP | disclosed |
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2024027116-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | PLA2G4A, PLA2G1B, PLA2G4B | OPRM1 4236/4885GRM5 2516/4885PIK3C3 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.